MEG3 and ovarian carcinoma: Evidence from clinical samples of epithelial ovarian cancer has shown that low MEG3 expression correlates with advanced stage disease, high grade pathology, and unfavorable survival outcomes, while higher levels of MEG3 are associated with improved therapeutic response and better prognosis (Xu et al., 2021).